This study demonstrates improved hemocompatibility and reduced inflammation in blood-contacting devices using a novel polyglycerol coating, suggesting safer medical interventions.
Blood‐contacting medical devices play a crucial role in clinical interventions, but their susceptibility to thrombosis and inflammation poses serious risks to treatment outcomes and patient safety. This study presents a novel coating that combines dendritic polyglycerol amine (dPGA), dendritic polyglycerol aldehyde (dPG‐CHO), and linear polyglycerol sulfate (lPGS) using a layer‐by‐layer self‐assembly method (LBL) on a polystyrene surface. The immobilization of dendritic polyglycerol enhances surface coverage, enabling the incorporation of a higher density of heparin‐mimicking lPGS, while the covalent bonding ensures the coating's long‐term stability. Compared to the pristine substrate, the coating significantly reduced platelet adhesion and activation. Notably, its hemocompatibility effects persist even after 30 days. Furthermore, co‐incubation experiments with RAW264.7 macrophages confirmed the anti‐inflammatory properties of the polyglycerol‐based coating. These results demonstrate that this heparin‐mimetic coating effectively improves the hemocompatibility of polystyrene and has the potential to be applied to other blood‐contacting materials.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: